207 related articles for article (PubMed ID: 34983784)
21. Antiangiogenesis: the fifth cancer treatment modality?
Camp-Sorrell D
Oncol Nurs Forum; 2003; 30(6):934-44. PubMed ID: 14603351
[TBL] [Abstract][Full Text] [Related]
22. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
De Bock K; Cauwenberghs S; Carmeliet P
Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
[TBL] [Abstract][Full Text] [Related]
23. [A concept of regulating tumor microenvironment immune and normalizing angiogenesis by Chinese medicine drug therapy for supporting zheng-qi to prop up root].
Xiong L; Tian SX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Feb; 30(2):201-4. PubMed ID: 20462053
[TBL] [Abstract][Full Text] [Related]
24. Vessel pruning or healing: endothelial metabolism as a novel target?
Cantelmo AR; Pircher A; Kalucka J; Carmeliet P
Expert Opin Ther Targets; 2017 Mar; 21(3):239-247. PubMed ID: 28081641
[TBL] [Abstract][Full Text] [Related]
25. Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients.
Liu M; Li H; Wang X; Jing L; Jiang P; Li Y
Cancer Med; 2020 Apr; 9(8):2660-2673. PubMed ID: 32073228
[TBL] [Abstract][Full Text] [Related]
26. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
Close A
Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
[TBL] [Abstract][Full Text] [Related]
27. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
28. Antiangiogenic cancer therapy.
Cao Y
Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic cancer treatment: The great discovery and greater complexity (Review).
Maj E; Papiernik D; Wietrzyk J
Int J Oncol; 2016 Nov; 49(5):1773-1784. PubMed ID: 27826619
[TBL] [Abstract][Full Text] [Related]
30. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
[TBL] [Abstract][Full Text] [Related]
31. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents.
Zhang Q; Bindokas V; Shen J; Fan H; Hoffman RM; Xing HR
Mol Cancer Ther; 2011 Jul; 10(7):1173-84. PubMed ID: 21586628
[TBL] [Abstract][Full Text] [Related]
32. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
33. Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model.
Chauvet N; Romanò N; Lafont C; Guillou A; Galibert E; Bonnefont X; Le Tissier P; Fedele M; Fusco A; Mollard P; Coutry N
Int J Cancer; 2017 May; 140(9):2150-2161. PubMed ID: 28152577
[TBL] [Abstract][Full Text] [Related]
34. Aflibercept a new target therapy in cancer treatment: a review.
Ricci V; Ronzoni M; Fabozzi T
Crit Rev Oncol Hematol; 2015 Dec; 96(3):569-76. PubMed ID: 26224565
[TBL] [Abstract][Full Text] [Related]
35. A mathematical model of angiogenesis and tumor growth: analysis and application in anti-angiogenesis therapy.
Zheng X; Sweidan M
J Math Biol; 2018 Nov; 77(5):1589-1622. PubMed ID: 30019238
[TBL] [Abstract][Full Text] [Related]
36. Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.
Shang B; Cao Z; Zhou Q
Front Med; 2012 Mar; 6(1):67-78. PubMed ID: 22460450
[TBL] [Abstract][Full Text] [Related]
37. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Sessa C; Guibal A; Del Conte G; Rüegg C
Nat Clin Pract Oncol; 2008 Jul; 5(7):378-91. PubMed ID: 18560389
[TBL] [Abstract][Full Text] [Related]
39. Molecular targets on blood vessels for cancer therapies in clinical trials.
Sato M; Arap W; Pasqualini R
Oncology (Williston Park); 2007 Oct; 21(11):1346-52; discussion 1354-5, 1367, 1370 passim. PubMed ID: 18080618
[TBL] [Abstract][Full Text] [Related]
40. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
Jain RK; Tong RT; Munn LL
Cancer Res; 2007 Mar; 67(6):2729-35. PubMed ID: 17363594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
